



## Anaptys Announces Participation in December Investor Conferences

November 25, 2025

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

### **Piper Sandler 37th Annual Healthcare Conference, New York, NY**

- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Tuesday, Dec. 2, 2025 at 1:30pm ET

### **Evercore 8th Annual Healthcare Conference, Coral Gables, FL**

- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Wednesday, Dec. 3, 2025 at 7:55am ET

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at <https://ir.anaptysbio.com/presentations-and-events>. Replays of the webcasts will be available for at least 30 days following the events.

### **About Anaptys**

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (*Jemperli* (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit [www.AnaptysBio.com](http://www.AnaptysBio.com) or follow us on [LinkedIn](#).

Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more [here](#).

### **Contact:**

Nick Montemarano  
Executive Director, Investor Relations  
858.732.0178  
[investors@anaptysbio.com](mailto:investors@anaptysbio.com)



Source: AnaptysBio, Inc.